Tag: PEPITES study
DBV Technologies Reports Positive Three-Year, Long Term Data from Phase III...
Patients demonstrated durable, long-term clinical benefit with an additional two years of treatment.
DBV Technologies Submits Biologics License Application to FDA for Viaskin Peanut...
This submission addresses the additional data needed on manufacturing procedures and quality controls which were communicated by the FDA in December.
DBV Applies for FDA License to Sell Viaskin Peanut Patch Therapy
"This submission represents a significant step forward for those families living with peanut allergy."
Positive Safety Results Reported for Viaskin Peanut Phase III Trial
The trial met its primary objective, demonstrating that Viaskin Peanut was well-tolerated with no new or unexpected adverse events.
Peanut Patch Phase III Enrollment Ends, Results Expected Toward End of...
The study received higher-than-expected patient demand.
